1-2 of 2
Amanda Schwab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4463.
https://doi.org/10.1182/blood-2023-179872
Published: 2023
Journal Articles

NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies

Anthony R. Mato, William G. Wierda, Weiyun Z. Ai, Ian W. Flinn, Michael Tees, Manish R. Patel, Krish Patel, Susan O'Brien, David A. Bond, Lindsey E. Roeker, Tanya Siddiqi, Michael L. Wang, Clare Sun, Omar Abdel-Wahab, Amanda Schwab, May Tan, Erin Meredith, Melissa A. Gessner, Su Young Kim, Adrian Wiestner, Alexey V Danilov
Journal: Blood
Blood (2022) 140 (Supplement 1): 2329–2332.
https://doi.org/10.1182/blood-2022-164772
Published: 2022